You are using an outdated browser. Please upgrade to the latest version for the best experience. Upgrade your browser now.
Skip Navigation

Drug Companies Retreat on Price Increases Under Pressure From California

Blue Shield of California was part of an effort to change state law to shed light on drug price increases, now it's having a national impact

In 2017, Blue Shield of California led advocacy efforts to pass Senate Bill 17, a measure to provide transparency in drug pricing for our members and purchasers. SB 17 requires drug manufacturers to inform purchasers 60 days in advance of an excessive price increase and an explanation as to why the increase was made. Our hope and past experience told us that simple transparency was an important first step to influence pricing practices by pharmaceutical manufacturers. 

Read the Bloomberg report on the shift by major drug makers on this issue.

 


Related Stories